Age-Related Muscle Loss (Sarcopenia): Mechanisms, Diagnosis, and Treatment
Sarcopenia (Greek: sarx flesh + penia loss) is the age-related progressive loss of muscle mass, strength, and function. It begins ~30s, accelerates after 60, and affects 10–30% of community-dwelling older adults.
Multifactorial Pathophysiology
| Mechanism | Key Changes |
|---|---|
| Neuromuscular | Motor unit loss (denervation), remodeling (collateral reinnervation → larger, fewer units), ↓firing rate, ↓proprioception |
| Muscle Fiber | Type II (fast) atrophy > Type I; fiber number ↓; satellite cell dysfunction; mitochondrial DNA mutations, ↓biogenesis |
| Protein Turnover | Anabolic resistance (blunted mTOR response to protein/insulin), ↑ubiquitin-proteasome, ↑autophagy, ↑inflammatory cytokines (IL-6, TNF-α) |
| Hormonal | ↓Testosterone, ↓GH/IGF-1, ↓DHEA, ↑cortisol, insulin resistance, ↓vitamin D |
| Vascular | Endothelial dysfunction → ↓capillary density, ↓nutrient/O₂ delivery |
| Behavioral | ↓Physical activity, ↓protein intake (anorexia of aging), ↓sunlight |
Clinical Consequences
- Physical: Gait slowing, fall risk ↑ 2–3x, disability (ADL/IADL), frailty phenotype.
- Metabolic: Insulin resistance, type 2 diabetes (muscle = major glucose disposal site).
- Clinical outcomes: Hospitalization, post-surgical complications, mortality ↑.
- Economic: US costs ~$18B/year (direct).
Diagnosis (EWGSOP2 / AWGS 2019)
- Case finding: SARC-F questionnaire (Strength, Assistance walking, Rise from chair, Climb stairs, Falls).
- Strength: Handgrip (<27 kg M, <16 kg F) or chair stand (≥15 sec ×5).
- Mass: DXA (appendicular lean mass/ht² <7.0 kg/m² M, <5.5 kg/m² F) or BIA.
- Performance: Gait speed <0.8 m/s, SPPB ≤8, 400m walk >6 min → severe sarcopenia.
Evidence-Based Interventions
Exercise (Cornerstone)
- Progressive Resistance Training (PRT): 2–3×/wk, 8–12 reps × 2–3 sets, 70–85% 1RM → ↑mass, strength, power, function.
- Power training: High-velocity concentric — improves functional tasks more than strength alone.
- Multicomponent: Balance, aerobic, flexibility.
Nutrition
- Protein: 1.2–1.6 g/kg/day; 25–30g/meal (leucine threshold ~2.5g); whey, dairy, lean meat, soy.
- Vitamin D: 800–2000 IU/day to maintain 25(OH)D >30 ng/mL.
- Omega-3 (2–3g EPA/DHA): Anti-inflammatory, may enhance anabolic sensitivity.
- Creatine monohydrate (3–5g/day): Adjunct to PRT — ↑strength, lean mass.
Pharmacologic (Investigational)
Myostatin inhibitors, SARMs, GH/IGF-1, testosterone (controversial), bimagrumab — not standard of care; only in trials.
Key message: Sarcopenia is preventable and treatable. Resistance exercise + adequate protein is the most potent non-pharmacologic intervention at any age. Start early, progress gradually, sustain lifelong.
Muscle Strains - Related Articles
- Lasix (Furosemide) and Muscle Cramps/Weakness: Hypokalemia Link
- Muscle Mass Percentage in Adults: Norms by Age and Sex
- Cardiac Muscle (Myocardium): Structure, Function, and Electrophysiology Explained
- Hamstring Injury Recovery: A Guide to Healing & Rehabilitation
- Advanced Knee Pain Treatments: Surgical Options & Relief
- Understanding and Managing Muscle Spasms: Causes & Relief
- Muscle Extension: Definition, Key Extensors, and Functional Importance
